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BACKGROUND: Between-country

variation in health care resource use and its impact on outcomes
in acute care settings have been challenging to disentangle from illness severity by using
administrative data.

abstract

We conducted a preplanned analysis employing patient-level emergency department
(ED) data from children enrolled in 2 previously conducted clinical trials. Participants aged 3 to
,48 months with ,72 hours of gastroenteritis were recruited in pediatric EDs in the United
States (N = 10 sites; 588 participants) and Canada (N = 6 sites; 827 participants). The primary
outcome was an unscheduled health care provider visit within 7 days; the secondary outcomes
were intravenous ﬂuid administration and hospitalization at or within 7 days of the index visit.
METHODS:

In adjusted analysis, unscheduled revisits within 7 days did not differ (adjusted odds
ratio [aOR]: 0.72; 95% conﬁdence interval (CI): 0.50 to 1.02). At the index ED visit, although
participants in Canada were assessed as being more dehydrated, intravenous ﬂuids were
administered more frequently in the United States (aOR: 4.6; 95% CI: 2.9 to 7.1). Intravenous
ﬂuid administration rates did not differ after enrollment (aOR: 1.4; 95% CI: 0.7 to 2.8; US
cohort with Canadian as referent). Overall, intravenous rehydration was higher in the United
States (aOR: 3.8; 95% CI: 2.5 to 5.7). Although hospitalization rates during the 7 days after
enrollment (aOR: 1.1; 95% CI: 0.4 to 2.6) did not differ, hospitalization at the index visit was
more common in the United States (3.9% vs 2.3%; aOR: 3.2; 95% CI: 1.6 to 6.8).
RESULTS:

CONCLUSIONS: Among

children with gastroenteritis and similar disease severity, revisit rates were
similar in our 2 study cohorts, despite lower rates of intravenous rehydration and
hospitalization in Canadian-based EDs.
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WHAT’S KNOWN ON THIS SUBJECT: Although the United States has the world’s
highest per capita medical costs, these expenditures are not associated with
improved outcomes. However, evaluations have rarely been focused on diseasespeciﬁc outcomes, employing detailed clinical patient-level data to untangle the
role of illness severity.
WHAT THIS STUDY ADDS: In this analysis of children with diarrhea, after
adjustment for severity characteristics, intravenous rehydration use was higher in
the United States. Thus, a deeper understanding of nonclinical inﬂuences on
decision-making is needed to reduce unnecessary intravenous rehydration use.
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ARTICLE

Although the United States has the
world’s highest per capita medical
costs,1 these expenditures are not
associated with improved
outcomes.2,3 In analyses, researchers
employing administrative data have
documented disparities for key
outcomes, such as life expectancy and
infant mortality. The aforementioned
analyses, however, lack patient-level,
illness severity data2 and are focused
on process variables, such as access,
use, and experience measures related
to chronic diseases or overall
metrics.2 With a disease-speciﬁc
approach, focused on an acute illness,
researchers, employing detailed
clinical patient-level data, have the
potential to clarify the effect of
a system (ie, country) of care on
outcomes.
With ∼30 million emergency
department (ED) visits by children
annually in the United States4 and
known variation across countries,5,6
understanding the impact that the
country where care is provided has
on outcomes is crucial to optimizing
care. In previous studies, researchers
have employed retrospective designs,
and the studies lacked test result data
and comprehensive, harmonized,
outcome data and thus are at risk of
misclassiﬁcation bias.5–7 Concerns
related to heterogeneity between
populations studied, the effects of
early disease identiﬁcation and
treatment, and limited patient-level
clinical data impair our ability to
draw conclusions about the inﬂuence
of health care systems on diseasespeciﬁc outcomes.
Acute gastroenteritis (AGE) is one of
the most common illnesses
prompting ED visits by children.4 The
recommended treatment of the
majority of affected children is the
provision of oral rehydration therapy
(ORT),8 with the selective use of
ondansetron in those with
dehydration and frequent
vomiting.9,10 This approach optimizes
resource use while avoiding the pain
associated with intravenous
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insertion.11 However, practice
variation is common within12 and
between13 countries, and numerous
institutions have focused on
promoting ORT.11,14
To overcome the limitations of
previous between-country
comparisons, we took advantage of
the simultaneous conduct of 2
probiotic clinical trials15,16 in children
with AGE in Canada and the United
States. In the trials, the researchers
followed nearly identical protocols
and data collection plans,17,18
permitting a comparison of resource
use, while providing detailed disease
severity data. We sought to determine
if the country of care (ie, United
States versus Canada) is
independently associated with
subsequent health care visits,
intravenous hydration, and
hospitalization after adjustment for
patient-level characteristics.

METHODS
Study Design and Population
This is a preplanned secondary
analysis of 2 parallel, multicenter,
pediatric ED-based studies conducted
in the United States (Pediatric
Emergency Care Applied Research
Network [PECARN] probiotic
study)16,17 and Canada (Pediatric
Emergency Research Canada [PERC]
Probiotic Regimen for Outpatient
Gastroenteritis Utility of Treatment
study).15,18 Children enrolled in the
PECARN study presented for care in 1
of 10 US-based EDs between July
2014 and June 2017. The PERC study
was performed at 6 Canadian EDs
between November 2013 and April
2017. These prospective, randomized,
trials enrolled 971 and 886 children,
respectively, with ethical review
board approval.
For the studies, researchers recruited
children aged 3 to ,48 months with
$3 watery stools in a 24-hour period
who were diagnosed as having AGE
and whose caregivers provided

informed consent. The maximal
duration of symptoms at the time of
screening was 72 hours and 7 days in
the Canadian and US studies,
respectively. To enhance the
similarity of the 2 study populations,
children recruited into the PECARN
study with duration of symptoms
.72 hours were excluded from this
analysis.
Children in both studies were
excluded if they or their direct
caregivers had risk factors for
bacteremia or a chronic
gastrointestinal disorder,17
pancreatitis, bilious emesis,
hematochezia, a known allergy to
investigational products, or the
inability to complete study follow-up.
The PECARN study excluded children
with allergies to erythromycin,
clindamycin, and b-lactam antibiotics.
Participants were randomly assigned
to receive either a 5-day course of
Lactobacillus GG (United States),
combined Lactobacillus rhamnosus
R0011 and Lactobacillus helveticus
R0052 product (Canada), or placebo.
Children lost to follow-up were
excluded.

Study Outcomes
The primary outcome was an
unscheduled health care provider
visit for AGE symptoms within 7 days
of recruitment. Visits booked before
ED discharge or previously scheduled
were not classiﬁed as outcomes.
Unscheduled visits were subanalyzed
on the basis of location: (1) ED and
(2) primary care provider. Secondary
outcomes analyzed at the index visit,
within 7 days of the index visit, and
overall included intravenous
insertion and hospitalization.

Data Collection
Research assistants collected
demographic and clinical data
during the index ED visit. Clinical
dehydration scale (CDS) scores
were assigned by trained research
nurses.19,20 Caregivers completed
follow-up surveys every 24 hours for
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a minimum of 5 days and until both
vomiting and diarrhea had ceased for
.24 hours. All participants reported
outcomes and health care use on day
14 after the index ED visit. A chart
review was performed to conﬁrm
caregiver report regarding revisits.

Enteropathogen Identiﬁcation
Before speciﬁc pathogens are
associated with disease severity,21
rectal swabs (FecalSwab; Copan
Diagnostics, Murrieta, CA), stool
specimens, or both were obtained
during the enrollment visit. A
bacterial culture was performed
locally. A multiplex nucleic acid panel
that detects 15 enteric viruses,
bacteria, and parasites (xTAG
Gastrointestinal Pathogen Panel;
Luminex, Austin, TX)22 was
performed at St Louis Children’s
Hospital’s research laboratory
(PECARN cohort) and the Provincial
Laboratory for Public Health at the
Alberta Precision Laboratories, in
Edmonton, Alberta, Canada (PERC
cohort).

Analysis
Categorical data are presented as
counts and percentages, and
continuous data are presented as
medians and interquartile ranges
(IQRs). The CDS score is reported
with means and SDs. We calculated
95% conﬁdence intervals (CIs) for
differences in proportions, medians,
and means using x2, inverted rank
score tests, and ordinary least square
methods, respectively. Both data sets
performed multiple imputation to
account for missing data, as
previously described.17,18 Imputation
models were stratiﬁed by country,
assumed data were missing at
random, and included key baseline
characteristics, trial group, and
efﬁcacy outcomes.
For the primary and secondary
outcomes, we used bivariable and
multivariable logistic regression to
calculate unadjusted and adjusted
odds ratios (aORs), respectively. For
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exploratory outcomes, negative
binomial regression was used to
calculate unadjusted and adjusted
rate ratios. Potential predictor
variables for the model were
predetermined on the basis of
biological plausibility. These included
age, sex, country (United States or
Canada), the number of diarrheal
stools and vomiting episodes in the
24 hours preceding enrollment, the
duration of diarrhea and vomiting
before enrollment, and CDS score.20
In a review of baseline variables
(Table 1), researchers identiﬁed 3
additional important characteristics,
which differed between countries and
were added to the models: previous
ED visits during the current illness
and ED ondansetron and intravenous
ﬂuid administration. Colinearity was
assessed by estimating the variance
inﬂation factors. The site was not
included as a random effect because
the number of sites is small, and it is
a subclassiﬁcation of the country.
Probiotic treatment allocation was
not included in the models because
previous analyses revealed no
association with the outcomes of
interest.17,18
The two-sided a level was set at .05.
Analyses were performed by using
SAS version 9.4 (SAS Institute, Inc,
Cary, NC).

RESULTS

6 1.3; difference: 20.5; 95% CI of the
difference: 20.6 to 20.3 points; Table
1). Children in the United States that
were excluded because of $72 hours
of symptoms at the time of
enrollment were similar to those that
were included, with the exception of
symptom duration, vomiting
frequency in the preceding 24 hours,
and ondansetron administration
(Supplemental Table 4).
Viral pathogens were identiﬁed in
43.7% and 51.7% of study
participants in the United States and
Canada, respectively (Supplemental
Table 5). Although investigations
were infrequently performed in both
countries, blood tests and diagnostic
imaging were more commonly
performed in the Canadian and US
cohorts, respectively (Table 2).

Primary Outcome
ED or primary care provider revisits
within 7 days of enrollment occurred
in 14.0% of the study cohort (11.6%
in United States; 17.3% in Canada); in
the adjusted analysis, they did not
differ between countries (aOR: 0.72;
95% CI: 0.50 to 1.02; Table 3). In
subanalysis of the primary outcome
based on the location of the revisit,
researchers identiﬁed that, although
primary care revisits did not differ
(aOR: 0.76; 95% CI: 0.45 to 1.28)
between groups, ED revisits were less
likely in the US cohort (aOR: 0.61;
95% CI: 0.39 to 0.95).

Participants
A total of 1415 eligible participants
are included (Fig 1); 588 (41.6%) and
827 (58.5%) were enrolled in US and
Canadian sites, respectively. US
participants were less likely to have
a previous ED visit during the current
illness (3.6% vs 10.0%; difference:
26.4%; 95% CI of the difference:
29.0% to 23.9%) and had more
diarrheal stools in the 24 hours
preceding randomization (median: 6
[IQR: 4–9] vs 5 [IQR: 3–8]; difference:
1; 95% CI of the difference: 0.5 to 1.5
episodes) but were less dehydrated
(mean CDS scores of 0.6 6 1.3 vs 1.1

Secondary Outcomes
Intravenous ﬂuid administration at
the index visit was more common in
the US cohort (17.0% vs 8.2%;
difference: 8.8%; 95% CI: of the
difference 5.2% to 12.4%), even after
covariate adjustment (OR: 4.6; 95%
CI: 2.9 to 7.1; P , .001). There was no
difference in the proportions of
children receiving intravenous
rehydration during the 7 days after
the index ED visit (aOR: 1.4; 95% CI:
0.7 to 2.8; P = .38, with the Canadian
cohort serving as the referent group).
Overall, intravenous ﬂuid
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TABLE 1 Cohort Descriptions
Country

Age in mo, median (IQR)
Male, n (%)
Race and/or ethnicity, n (%)a
White non-Hispanic and non-Latino
Hispanic or Latino
Black non-Hispanic and non-Latino
Other non-Hispanic and non-Latino
Distance to hospital, km,b median (IQR)
Child has a primary medical doctor, n (%)
Previous ED visit for the current illness, n (%)
CDS score, continuous, mean (SD)c
Baseline MVS score, median (IQR)
Maximum temperature (Celsius), median (IQR)
Received antibiotics past 14 d, n (%)
Received rotavirus vaccine, n (%)
Diarrhea and vomiting severity
No. diarrheal episodes previous 24 h, median (IQR)
Duration of diarrhea at presentation, median (IQR), h
Presence of vomiting at presentation, n (%)
No. vomiting episodes in previous 24 h,d median (IQR)
Duration of vomiting at presentation, median (IQR), hd
Index ED visit interventions, n (%)
IV ﬂuids administered during index visit
IV ﬂuids administered at index visit or within 7 d
Ondansetron given in the ED, n (%)
Oral
Intravenous
Patient was admitted to the hospital from the ED, n (%)
Ondansetron administered at home, postindex ED visit, n (%)

Difference (95% CI)

Canada PERC Study (N = 827)

US PECARN Study (N = 588)

16.0 (10.0–24.0)
472 (57.1)

17.4 (10.6–28.3)
309 (52.6)

1.4 (20.6 to 3.3)
24.5% (29.8 to 0.7)

—
—
—
—
10.2 (5.3–15.9)
757 (91.5)
83 (10.0)
1.1 (1.34)
12 (10–13)
38.0 (37.0–39.4)
110 (13.3)
396 (63.5)

115 (20.2)
202 (35.6)
207 (36.4)
44 (7.7)
7.8 (3.9–14.4)
557 (94.9)
21 (3.6)
0.6 (1.25)
11 (9–13)
37.8 (37.0–39.4)
46 (7.9)
259 (66.6)

—
—
—
22.4 (23.5 to 21.3)
3.4 (0.8 to 6)
26.4 (29 to 23.9)
20.5 (20.6 to 20.3)
21 (21.5 to 20.5)
20.2 (20.7 to 0.3)
25.4 (28.6 to 22.2)
3.1 (22.9 to 9.1)

5 (3–8)
32.4 (22.5–51.8)
635 (76.8)
4 (2–7)
36.4 (17.5–52.0)

6 (4–9)
35.6 (21.5–52.0)
448 (76.3)
4 (2–6)
29.2 (16.2–49.6)

1 (0.5 to 1.5)
3.0 (21.2 to 7.1)
20.5% (24.9 to 4.0)
0 (20.6 to 0.6)
27.1 (210.9 to 23.2)

68 (8.2)
79 (9.6)
183 (22.2)
176 (21.3)
7 (0.8)
19 (2.3)
13 (1.8)

100 (17.0)
107 (18.2)
292 (49.7)
264 (44.9)
28 (4.8)
23 (3.9)
59 (10.1)

8.8 (5.2 to 12.4)
8.6 (4.9 to 12.4)
27.5 (22.6 to 32.4)
23.6 (18.7 to 28.5)
3.9 (2.1 to 5.7)
1.6 (20.3 to 3.5)
8.3 (5.7 to 10.9)

Medians (IQR) and differences in medians with 95% CIs estimated by using the inverted rank score test are shown for continuous characteristics, with the exception of the CDS score,
which displays mean (SD) with difference in means and 95% ordinary least square CI; n (%) and differences in proportions with 95% Wald CI are shown for categorical characteristics.
Missing values are as follows (Canada and United States): distance to hospital (1 and 3), primary medical doctor (0 and 1), previous ED visit (0 and 5), dehydration score (0 and 4),
number of diarrheal episodes (1 and 1), diarrhea duration (195 and 14), number of vomit episodes (0 and 1), ED intravenous ﬂuids (1 and 0), ED ondansetron (1 and 0), and admitted (0
and 1). IV, intravenous; MVS, modiﬁed Vesikari scale; —, not applicable.
a Race and ethnicity data were unavailable for the Canada (PERC) cohort.
b Distance was calculated as the geodetic distance between a patient’s residence and the hospital zip (postal) code.
c Dehydration was assessed by using the CDS score.20,23 A score of 0 indicates no dehydration, scores of 1 to 4 indicate some dehydration, and scores of 5 to 8 indicate moderate-to-severe
dehydration.
d Out of those experiencing vomiting.

administration was more common
in the US cohort (18.2% vs 9.6%;
difference: 8.6%; 95% CI: of the
difference 4.9% to 12.4%). This
ﬁnding persisted after adjustment
(aOR: 3.8; 95% CI: 2.5 to 5.7; P ,
.001). In Figure 2, we illustrate that,
relative to the US sites, intravenous
ﬂuids were administered less often at
the Canadian sites (ie, are grouped
closer to the y-axis), without a higher
probability of a revisit (similar height
on y-axis).
We found no difference in the
proportions of children in the United
States, relative to the Canadian
cohort, who required hospitalization
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during the 7 days after randomization
(aOR: 1.1; 95% CI: 0.4 to 2.6; P = .87).
Although hospitalization at the index
ED visit and overall did not vary by
country (Table 1), adjustment for
a priori identiﬁed covariates revealed
higher overall (aOR: 2.2; 95% CI: 1.2
to 4.0; P = .009) and index visit (aOR:
3.2; 95% CI: 1.6 to 6.8; P = .002)
hospitalization rates in the US cohort.

Exploratory Outcomes
Children in the US cohort experienced
a lower maximal number of diarrheal
and vomiting episodes in a 24-hour
period and shorter duration of
vomiting after an index ED visit;
Table 3.

DISCUSSION
In this study, we determined that
children with AGE managed in the
United States experienced greater
rates of intravenous rehydration and
hospitalization at the index visit,
compared with those managed in
Canadian-based EDs. This more
interventional approach did not lead
to a reduction in overall unscheduled
AGE-related health care visits or
intravenous rehydration during the
subsequent 7 days, after adjustment
for patient-level characteristics. With
these ﬁndings, it is suggested that
more judicious use of health care
resources could be achieved in the ED
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during venipuncture and intravenous
catheter insertion,27 avoiding
unnecessary procedures is a
fundamental priority. Additionally,
unnecessary intravenous rehydration
has ﬁnancial implications: on the basis
of data provided by 4 of our US-based
study sites, 2 hours of intravenous
ﬂuid therapy is associated with
a mean charge of $892 (range:
$603–$1136).

FIGURE 1
Study participants.

without leading to adverse outcomes
or undesirable consequences.
In children with AGE, intravenous
rehydration use is associated with
dysnatremia, acidosis, ﬂuid overload,
and, in severe cases, seizures and

death.24,25 However, perhaps more
importantly, intravenous cannula
insertion is almost universally
associated with pain.26 Although both
pharmacologic and nonpharmacologic
techniques are available to reduce
children’s acute pain and distress

TABLE 2 Index ED Visit Clinically Ordered (ie, Not Part of Research) Laboratory Investigations and
Diagnostic Imaging
Country

Urine dipstick or
urinalysis
Urine culture
Serum electrolytes
Blood gas
Complete blood count
Blood culture
Stool viral studiesa
Stool bacterial culturea
Chest radiograph
Abdominal radiograph
Abdominal ultrasound

Difference, %a (95% Wald
CIs)

Canada PERC Study; n (%) (N
= 827)

US PECARN Study;
n (%)
(N = 588)

78 (9.4)

56 (9.5)

0.1 (23 to 3.2)

51 (6.2)
84 (10.2)
51 (6.2)
81 (9.8)
31 (3.7)
Not collected
81 (9.9)
24 (2.9)
1 (0.1)
4 (0.5)

41 (7.0)
75 (12.8)
31 (5.3)
37 (6.3)
10 (1.7)
16 (2.7)
45 (7.7)
15 (2.6)
17 (2.9)
19 (3.2)

0.8 (21.8 to 3.4)
2.6 (20.8 to 6)
20.9 (23.3 to 1.5)
23.5 (26.3 to 20.7)
22 (23.7 to 20.4)
—
22.2 (25.2 to 0.7)
20.4 (22.1 to 1.4)
2.8 (1.4 to 4.1)
2.7 (1.2 to 4.3)

Missing values are as follows (Canada and US): stool culture (7 and 0). —, not applicable.
a Does not include stool testing performed as part of the research protocols.
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Because both countries have similar
AGE management guidelines that
promote the use of ORT in the
absence of severe dehydration, the
differences identiﬁed are unlikely
related to variations in standards of
care.8,28 Although we found that the
higher intravenous rehydration rate
in the United States may reduce the
likelihood of 7-day ED revisits, this
ﬁnding was only detected in
subgroup analysis, and the overall
a priori identiﬁed primary outcome,
any revisit, did not differ between
groups. Moreover, with an upper
bound of the 95% CI of 0.95, 192
children would need to be treated in
the US model of care to prevent 1
unscheduled ED revisit. Given our
estimate of an 8.8% absolute
difference in index ED visit
intravenous hydration rates (ie, 1 in
every 11 children), nearly 17
additional children would need to be
administered intravenous ﬂuids to
prevent 1 ED revisit. Supportive
evidence that targeted quality
improvement efforts to reduce
intravenous rehydration use can do
so without increasing ED revisits was
provided by researchers of a study
from Seattle, which revealed that
a 22% absolute reduction in the
intravenous rehydration rate had no
effect on the 72-hour revisit rate.14
Although, in our study, we do
not discern to what extent the
intravenous rehydration rates are
attributable to systematic differences
in health care systems, health seeking
behaviors, or practice patterns,
we did determine that intravenous
rehydration use could be curtailed
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TABLE 3 Primary and Secondary Outcome Measures
Canada PERC Study US PECARN Study
(N = 827)
(N = 588)
Primary outcomes
ED or primary care visit within 7 d of
discharge
ED revisit within 7 d of dischargec
Primary care visit within 7 d of dischargec
Secondary outcomes
IV ﬂuids administered during index visit
IV rehydration within 7 d of discharge
IV ﬂuids administered during index visit or
within 7 d of discharge
Patient was admitted to the hospital from
the ED
Hospitalization within 7 d of discharge
Hospitalization within 7 d (including index
visit)
Exploratory outcomes
Duration of diarrhea postenrollment, h
Maximal No. diarrheal episodes per 24 h
period postenrollment
Duration of vomiting postenrollment, h
Maximal number of vomiting episodes per
24 h period postenrollment

Unadjusted Odds Ratio
or Rate Ratio
(95% CI)a

Unadjusted
P

aOR or Rate
Ratio (95% CI)b

Adjusted
P

130 (17.3%)

68 (11.6%)

0.72 (0.52 to 0.98)

.04

0.72 (0.5 to 1.02)

.07

87 (11.7%)
54 (6.5%)

40 (6.8%)
30 (5.1%)

0.63 (0.43 to 0.93)
0.79 (0.5 to 1.25)

.02
.32

0.61 (0.39 to 0.95)
0.76 (0.45 to 1.28)

.03
.30

68 (8.2%)
22 (3.0%)
79 (9.6%)

100 (17.0%)
16 (2.7%)
107 (18.2%)

2.29 (1.65 to 3.19)
1.08 (0.56 to 2.06)
2.13 (1.55 to 2.91)

,.001
.82
,.001

4.56 (2.93 to 7.11)
1.38 (0.67 to 2.84)
3.76 (2.49 to 5.67)

,.001
.38
,.001

19 (2.3%)

23 (3.9%)

1.75 (0.94 to 3.24)

.076

3.24 (1.55 to 6.77)

.002

18 (2.5%)
34 (4.1%)

9 (1.5%)
31 (5.3%)

0.77 (0.35 to 1.74)
1.33 (0.81 to 2.19)

.54
.27

1.08 (0.44 to 2.63)
2.19 (1.22 to 3.95)

.87
.009

46.2 (0.1 to 85.0)
3.0 (1.0 to 5.0)

51.1 (21.6 to 87.1)
3.0 (2.0 to 4.0)

0.85 (0.74 to 0.98)
0.83 (0.75 to 0.92)

.02
,.001

0.91 (0.79 to 1.06)
0.84 (0.76 to 0.92)

.22
,.001

0.0 (0.0 to 38.6)
0.0 (0.0 to 2.0)

0.0 (0.0 to 12.5)
0.0 (0.0 to 1.0)

0.55 (0.39 to 0.77)
0.66 (0.53 to 0.82)

,.001
,.001

0.51 (0.35 to 0.75)
0.68 (0.54 to 0.86)

,.001
.001

All outcomes include health care use through 7 d after enrollment consistent with gastroenteritis. Canada is used as reference category. Odds ratios are shown for primary and
secondary outcomes, and rate ratios are shown for the exploratory outcomes.
a Overall rates from the United States and Canadian studies, including both placebo and probiotic-treated patients. Unadjusted odds ratios compare these groups without adjusting for
other factors.
b All models are adjusted for country, the number of diarrheal stools and vomiting episodes in the 24 h before enrollment, the duration of vomiting and diarrhea before enrollment,
dehydration scale, age, sex, previous ED visit during current illness, and ED ondansetron administration. Primary outcomes are additionally adjusted for intravenous ﬂuid administration
at the index visit.
c Post hoc analysis.

without incurring adverse
outcomes.29,30 Two decades ago, the
use of ORT in lieu of intravenous
rehydration was promoted as
a “reverse-transfer” of technology
from low- to high-income countries.31
Nonetheless, the deimplementation of
intravenous rehydration remains
a challenge, in part because of
a possible reluctance of physicians to
abandon practices that provide
limited beneﬁts.32
ED revisits are important metric of
ED care because they are common
and costly,33 occurring within 72
hours in 3% to 5% of all pediatric ED
visits,34–37 and nearly 20% of all
children with ED revisits are
hospitalized.34,35,38 Variables
associated with revisits in both
countries include younger age, illness
acuity and progression, and social
factors.34,36,37,39 Although previous
work has revealed similar ED visit
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rates and patterns in the 2
countries,40 the drivers appear to
differ; although long wait times to see
primary care physicians hinder nonED–based follow-up in Canada, the
high cost of care is the culprit in the
United States.41 In our study, we did
note that a greater proportion of all
unscheduled follow-up visits
occurred in EDs in the Canadian
cohort.
AGE is associated with
a disproportionately high revisit
rate, especially when based on
patient-reported revisit data. In our
study, ED revisit rates (7% and 12%
in the United States and Canada,
respectively) were higher than
those suggested by aforementioned
database studies (3% to 5%),34–37
in which researchers often fail to
include revisits to EDs other
than those in which the patient
initially presented. As it relates to

understanding baseline AGE revisits,
there is signiﬁcant variability on the
basis of the study population. In
a tertiary-care–center Canadian
study of 174 children who received
intravenous ﬂuids, 18% of
participants had an ED revisit
within 7 days.42 At the same
institution, in a database study that
included 3346 children, researchers
reported a 16% 7-day ED revisit
rate.43 However, in a provincial
database study that included 55 520
discharged children, the 72-hour
ED revisit rate was only 4.3%.44
Interestingly, in a US-based 21institution study, the median ED
revisit rate among children diagnosed
with AGE was only 2.2%.45 These
between-country differences warrant
further exploration but may be
partially explained by differences
in the ability of databases to
completely capture ED revisits.
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Our study has several limitations.
The original United States data set
included 355 children with .72
hours of symptoms who were
excluded from our analysis to permit
a direct comparison of similar
populations. Although we adjusted
for the most important clinical
characteristics inﬂuencing the
decision to administer intravenous
rehydration, social drivers, such as
parental leave policies and
preferences48 and the medicolegal
environment,49 were not included
in our analysis. However, many of
these factors are country speciﬁc
and, therefore, are integrated into
the “country” variable in our
models.

FIGURE 2
Overlapping prediction ellipses (1 SD)44 demonstrating the country-speciﬁc tendencies of the study
sites to administer intravenous ﬂuids and have patients with a revisit within 7 days. The center of
the ellipse represents the sample mean. The size of the individual symbols are directly correlated
with the number of patients recruited at a given site. IV, intravenous; PROGUT, Probiotic Regimen for
Outpatient Gastroenteritis Utility of Treatment.

Provincial databases available in
Canada incorporate all EDs in the
province, whereas the data reported
in US reports generally include only
site-speciﬁc ED revisits.
Inter- and intrainstitutional data have
revealed wide variability in
intravenous rehydration rates
between sites12 and practitioners.11
However, in multidisciplinary quality
improvement initiatives focused on
reduced intravenous rehydration,
sustained reductions in intravenous
rehydration use, ED length of stay,
and costs have been achieved.11,14
Key drivers of intravenous ﬂuid
administration include parental
acceptance of ORT, provider
knowledge of local and national
guidelines, challenges with hydration
assessment, and primary care
provider desires.11 Although our
study did not speciﬁcally explore
drivers of intravenous rehydration
use, one notable difference between
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countries is the ﬁnancial
underpinnings of health care delivery.
Although institutions in the United
States receive greater reimbursement
for more complex care, with ED
revenues exceeding costs by $6.1
billion nationally in 2009,46 EDs in
Canada operate on ﬁxed annual
budgets provided by provincial
governments, which leads them to
adopt approaches to minimize
expenditures. These ﬁnancial
implications may intersect with
parental and primary care provider
expectations, which, thus, may play
a greater role in the delivery of
health care in the United States,47
relative to Canada. By demonstrating
that increased intravenous
rehydration use does not lead to an
overall reduction in unscheduled
visits, in this study, we provide
important data that can inform
conversations with caregivers and
primary care physicians of children
with AGE.

Although the frequency of previous
ED visits differed between countries
and these visits may have been
associated with testing or
interventions, in our adjusted models,
we included this variable, and, thus,
our adjusted models do not explain
our ﬁndings. We also did not include
prescheduled follow-up primary
care or ED visits; in a previous
report, the latter accounted for
17% of all pediatric ED revisits.
Although primary care follow-up is
recommended for children with AGE
by over three-quarters of pediatric ED
physicians in the United States, they
are desired by less than one-third of
primary care physicians and, thus,
likely reﬂect overuse, rather than
a method of preventing ED revisits.50
Moreover, because planned revisits
are anecdotally more common in
the United States, with our data, we
likely underestimate primary care
and, possibly, ED revisits in our US
cohort. Patient satisfaction and costs
are not included in this analysis;
these outcomes are important
considerations for future exploration.
Although, in our study, we included
a limited number of academic centers
within each country, between-site
variability was small (intraclass
correlation coefﬁcient = 0.04 for
revisits), which supports our
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“country” model approach.
Although, in other reports (including
pediatric ED physician self-report)51
on the use of intravenous
rehydration, researchers support
our ﬁndings of lower usage rates in
Canada (relative to the United
States),14,52–54 generalizing our
ﬁndings to other EDs must be done
with caution.

CONCLUSIONS
Despite greater rates of intravenous
rehydration and hospitalization in

children with AGE in US-based EDs,
when compared with Canadianbased EDs, we found no differences
in overall unscheduled revisits
after ED discharge. Thus, judicious
use of health care resources may
be possible without leading to
adverse outcomes or undesirable
consequences. This points to an
urgent need to better understand
the drivers of intravenous
rehydration use and hospitalization to
improve the care of children with
AGE.
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